KR101026929B1 - 트리사이클릭 트롬빈 수용체 길항제 - Google Patents

트리사이클릭 트롬빈 수용체 길항제 Download PDF

Info

Publication number
KR101026929B1
KR101026929B1 KR1020047016409A KR20047016409A KR101026929B1 KR 101026929 B1 KR101026929 B1 KR 101026929B1 KR 1020047016409 A KR1020047016409 A KR 1020047016409A KR 20047016409 A KR20047016409 A KR 20047016409A KR 101026929 B1 KR101026929 B1 KR 101026929B1
Authority
KR
South Korea
Prior art keywords
delete delete
alkyl
nhc
pharmaceutically acceptable
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020047016409A
Other languages
English (en)
Korean (ko)
Other versions
KR20040099441A (ko
Inventor
착칼라만닐사무엘
클라스비마틴씨.
그린리윌리암제이.
왕유구앙
치아얀
벨트리엔리코피.
첼리아마리아판
우웬쑤
Original Assignee
쉐링 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29250954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101026929(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 쉐링 코포레이션 filed Critical 쉐링 코포레이션
Publication of KR20040099441A publication Critical patent/KR20040099441A/ko
Application granted granted Critical
Publication of KR101026929B1 publication Critical patent/KR101026929B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020047016409A 2002-04-16 2003-04-14 트리사이클릭 트롬빈 수용체 길항제 Expired - Fee Related KR101026929B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37307202P 2002-04-16 2002-04-16
US60/373,072 2002-04-16
PCT/US2003/011510 WO2003089428A1 (en) 2002-04-16 2003-04-14 Tricyclic thrombin receptor antagonists

Publications (2)

Publication Number Publication Date
KR20040099441A KR20040099441A (ko) 2004-11-26
KR101026929B1 true KR101026929B1 (ko) 2011-04-04

Family

ID=29250954

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047016409A Expired - Fee Related KR101026929B1 (ko) 2002-04-16 2003-04-14 트리사이클릭 트롬빈 수용체 길항제

Country Status (33)

Country Link
US (3) US7304078B2 (enExample)
EP (5) EP2062890B1 (enExample)
JP (2) JP4558331B2 (enExample)
KR (1) KR101026929B1 (enExample)
CN (1) CN1659162B (enExample)
AR (1) AR039570A1 (enExample)
AT (3) ATE455774T1 (enExample)
AU (1) AU2003221932B2 (enExample)
BR (1) BRPI0309309B8 (enExample)
CA (1) CA2482858C (enExample)
CY (3) CY1107184T1 (enExample)
DE (3) DE60331114D1 (enExample)
DK (2) DK1495018T3 (enExample)
EC (1) ECSP045368A (enExample)
ES (3) ES2357876T3 (enExample)
FR (1) FR15C0047I2 (enExample)
IL (1) IL164585A (enExample)
LT (1) LTC1495018I2 (enExample)
LU (1) LU92759I2 (enExample)
MX (1) MXPA04010308A (enExample)
MY (1) MY144040A (enExample)
NL (1) NL300746I2 (enExample)
NO (2) NO330500B1 (enExample)
NZ (2) NZ575139A (enExample)
PE (1) PE20040412A1 (enExample)
PL (1) PL214718B1 (enExample)
PT (2) PT1495018E (enExample)
RU (2) RU2329264C9 (enExample)
SG (1) SG164279A1 (enExample)
SI (2) SI1495018T1 (enExample)
TW (1) TWI343919B (enExample)
WO (1) WO2003089428A1 (enExample)
ZA (1) ZA200408342B (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
MXPA06013903A (es) * 2004-05-28 2007-01-26 Schering Corp Analogos restringidos de himbacina como antagonistas del receptor de trombina.
WO2006042017A2 (en) * 2004-10-06 2006-04-20 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
AR056262A1 (es) * 2005-01-14 2007-10-03 Schering Corp Preparacion de alcoholes propargilicos y esteres intermediarios de analogos de himbacina
WO2006076452A2 (en) 2005-01-14 2006-07-20 Schering Corporation An exo-selective synthesis of himbacine analogs
CN101193880B (zh) 2005-01-14 2012-08-22 先灵公司 喜巴辛类似物的外型和非对映立体选择合成
MX2007008631A (es) * 2005-01-14 2007-09-12 Schering Corp Sintesis de analogos de himbacina.
US7541471B2 (en) * 2005-01-14 2009-06-02 Schering Corporation Synthesis of himbacine analogs
EP1863778B1 (en) * 2005-03-31 2015-12-30 Merck Sharp & Dohme Corp. Spirocyclic thrombin receptor antagonists
WO2007075808A2 (en) * 2005-12-20 2007-07-05 Schering Corporation Methods for preventing and/or treating a cell proliferative disorder
US20070202140A1 (en) * 2005-12-22 2007-08-30 Veltri Enrico P Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery
PE20080183A1 (es) * 2006-04-06 2008-03-10 Schering Corp Terapias de combinacion de tra
EP2266976B1 (en) * 2006-04-13 2013-07-31 Merck Sharp & Dohme Corp. Fused ring thrombin receptor antagonists
MX2009000107A (es) * 2006-06-29 2009-01-23 Schering Corp Antagonistas del receptor de trombina biciclicos y triciclicos sustituidos.
AR061727A1 (es) * 2006-06-30 2008-09-17 Schering Corp Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
DE102006036023A1 (de) 2006-08-02 2008-02-07 Sanofi-Aventis Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
KR20090058583A (ko) * 2006-10-04 2009-06-09 쉐링 코포레이션 힘바신의 개질된 트리사이클릭 단위를 기본으로 하는 트롬빈 수용체 길항제
JP2010505842A (ja) * 2006-10-04 2010-02-25 シェーリング コーポレイション トロンビン受容体拮抗薬としての二環式誘導体および三環式誘導体
WO2008079260A2 (en) * 2006-12-22 2008-07-03 Schering Corporation Disintegration promoters in solid dose wet granulation formulations
CA2681597A1 (en) * 2007-03-23 2008-10-02 Schering Corporation Reduction of adverse events after percutaneous intervention by use of a thrombin receptor antagonist
BRPI0907486A2 (pt) 2008-02-05 2015-07-14 Sanofi Aventis Triazolpiridazinas como inibidores de par1, sua produção e uso como medicamentos
MY148732A (en) 2008-02-05 2013-05-31 Sanofi Aventis Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
WO2009124103A2 (en) * 2008-04-02 2009-10-08 Schering Corporation Combination therapies comprising par1 antagonists with par4 antagonists
EP2300435A2 (en) 2008-05-19 2011-03-30 Schering Corporation Heterocyclic compounds as factor ixa inhibitors
SI2438060T1 (sl) * 2009-06-04 2014-04-30 Merck Sharp & Dohme Corp. Aktivni metabolit trombin receptorskega antagonista
WO2010144339A2 (en) 2009-06-08 2010-12-16 Schering Corporation A thrombin receptor antagonist and clopidogrel fixed dose tablet
AR077695A1 (es) 2009-08-04 2011-09-14 Schering Corp Derivados de pirimidina como inhibidores del factor ixa
PL2558465T3 (pl) 2010-04-16 2015-05-29 Sanofi Sa Trycykliczne pirydylo-winylo-pirole jako inhibitory receptora aktywowanego proteazą 1 (PAR1)
ES2527535T3 (es) 2010-04-16 2015-01-26 Sanofi Piridil-vinil-pirazolo-quinolinas como inhibidores de PAR1
KR101303348B1 (ko) 2010-06-25 2013-09-03 한국화학연구원 트롬빈 수용체 길항제인 ［6＋5］접합 바이사이클, 그의 제조방법 및 그를 포함하는 약제학적 조성물
WO2013134012A1 (en) 2012-03-06 2013-09-12 Merck Sharp & Dohme Corp. Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists
EP3024550A4 (en) 2013-07-22 2016-12-07 Merck Sharp & Dohme CO-CRYSTAL FROM THE PAR-1 RECEPTOR ANTAGONIST VORAPAXAR AND ASPIRIN
US20160200715A1 (en) 2013-08-22 2016-07-14 Merck Sharp & Dohme Corp. Preparation and use of 7a-heterocycle substituted- 6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists
US9701669B2 (en) 2013-08-22 2017-07-11 Merck Sharp & Dohme Corp. Preparation and use of 7a-amide substituted- 6,6-difluoro bicyclic himbacine derivatives as PAR-1 receptor antagonists
US9808473B2 (en) 2013-08-22 2017-11-07 Merck Sharp & Dohme Corp. Preparation and use of 3-pyridyl substituted-6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists
FR3014693B1 (fr) 2013-12-16 2016-01-08 Pf Medicament Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
EP3131897B8 (en) 2014-04-16 2022-08-03 Merck Sharp & Dohme LLC Factor ixa inhibitors
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN105985303B (zh) * 2015-02-13 2020-08-14 上海彩迩文生化科技有限公司 抗凝血剂的制备方法、中间体及其制备方法
CN106478608A (zh) * 2015-09-01 2017-03-08 博瑞生物医药（苏州）股份有限公司 沃拉帕沙的硫酸盐的结晶多晶型物
CN106749201A (zh) * 2015-11-25 2017-05-31 博瑞生物医药（苏州）股份有限公司 一种沃拉帕沙及其中间体的制备方法
TR201601548A2 (tr) * 2016-02-05 2018-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu
WO2017134200A1 (en) * 2016-02-05 2017-08-10 Sanovel Ilac Sanayi Ve Ticaret A.S. A novel pharmaceutical composition of vorapaxar and metoprolol
CN107304200B (zh) * 2016-04-22 2021-09-21 江苏天士力帝益药业有限公司 一种新的喜巴辛类似物及其在医药中的应用
CN106236779A (zh) * 2016-08-22 2016-12-21 孔五 一种脐带血富血小板血浆prp的制备方法
FR3090317B1 (fr) 2018-12-19 2021-05-07 Cvasthera Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale
CN110407819B (zh) * 2019-08-02 2020-06-26 牡丹江医学院 一种作为预防外科手术并发症的凝血酶受体拮抗剂
US20210113536A1 (en) * 2019-10-21 2021-04-22 United States Government as Represented by the Department of Veteran Affairs Methods and compositions for detecting and treating venous thromboembolism
FR3109089B1 (fr) 2020-04-08 2023-04-14 Cvasthera Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales
WO2022018156A1 (en) 2020-07-22 2022-01-27 Janssen Pharmaceutica Nv Compounds useful as factor xia inhibitors
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
US11897880B2 (en) 2021-04-30 2024-02-13 Janssen Pharmaceutica Nv 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
US12286429B2 (en) 2021-07-22 2025-04-29 Janssen Pharmaceutica Nv 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors
US11958856B2 (en) 2021-07-22 2024-04-16 Janssen Pharmaceutica Nv Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
FR3134314A1 (fr) 2022-04-08 2023-10-13 Cvasthera Composition pharmaceutique à base de vorapaxar et son utilisation pour le traitement des maladies inflammatoires intestinales

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
TW197435B (enExample) * 1990-11-22 1993-01-01 Takeda Pharm Industry Co Ltd
GB9102862D0 (en) * 1991-02-11 1991-03-27 Erba Carlo Spa N-imidazolyl derivatives of substituted or alkoxymino tetrahydronaphthalenes and chromans
IL106197A (en) 1992-07-30 1999-11-30 Cor Therapeutics Inc Agagonists for the rhombin receptors and pharmaceutical preparations containing them
US5576328A (en) 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
US6063847A (en) * 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
ATE266025T1 (de) * 1997-11-25 2004-05-15 Schering Corp Thrombin-rezeptor antagonisten
FR2779726B1 (fr) 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
US20040192753A1 (en) 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7488742B2 (en) 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
TWI302913B (en) * 2000-06-15 2008-11-11 Schering Corp Thrombin receptor antagonists
PL371948A1 (en) 2001-10-18 2005-07-11 Schering Corporation Himbacine analogues as thrombin receptor antagonists

Also Published As

Publication number Publication date
PL214718B1 (pl) 2013-09-30
RU2004133375A (ru) 2005-07-10
CY1107184T1 (el) 2012-10-24
LU92759I2 (en) 2015-08-31
AU2003221932B2 (en) 2007-11-22
ES2297150T3 (es) 2008-05-01
SG164279A1 (en) 2010-09-29
ATE378330T1 (de) 2007-11-15
ES2297150T7 (es) 2012-03-16
NO330500B1 (no) 2011-05-02
IL164585A (en) 2010-11-30
TWI343919B (en) 2011-06-21
PL373332A1 (en) 2005-08-22
CY1111363T1 (el) 2015-08-05
DE60331114D1 (de) 2010-03-11
ES2357876T3 (es) 2011-05-03
HK1129893A1 (en) 2009-12-11
DE60317493T3 (de) 2018-07-12
EP1860106A1 (en) 2007-11-28
EP1982984A3 (en) 2008-10-29
DK2065384T3 (da) 2011-05-02
FR15C0047I1 (enExample) 2015-08-28
RU2329264C2 (ru) 2008-07-20
CN1659162A (zh) 2005-08-24
US7304078B2 (en) 2007-12-04
CY2015029I2 (el) 2016-04-13
NO20044963L (no) 2004-11-15
RU2008106401A (ru) 2009-08-27
NO2015016I1 (no) 2015-07-20
JP4558331B2 (ja) 2010-10-06
ATE455774T1 (de) 2010-02-15
EP1860106B1 (en) 2010-01-20
FR15C0047I2 (fr) 2016-05-06
IL164585A0 (en) 2005-12-18
BRPI0309309B1 (pt) 2018-09-04
HK1123302A1 (en) 2009-06-12
JP2005528406A (ja) 2005-09-22
US20070270439A1 (en) 2007-11-22
EP1495018B1 (en) 2007-11-14
DK1495018T3 (da) 2008-02-18
SI2065384T1 (sl) 2011-05-31
BRPI0309309B8 (pt) 2021-05-25
NL300746I1 (enExample) 2016-01-21
CA2482858A1 (en) 2003-10-30
ZA200408342B (en) 2006-05-31
CY2015029I1 (el) 2016-04-13
DE60335679D1 (de) 2011-02-17
MXPA04010308A (es) 2005-02-03
US20070179187A1 (en) 2007-08-02
JP2010132710A (ja) 2010-06-17
ECSP045368A (es) 2005-01-03
ATE494284T1 (de) 2011-01-15
LTC1495018I2 (lt) 2017-04-10
EP2062890A1 (en) 2009-05-27
PT1495018E (pt) 2008-02-19
NZ535880A (en) 2007-11-30
US7713999B2 (en) 2010-05-11
DE60317493T2 (de) 2008-09-18
PT2065384E (pt) 2011-03-16
PE20040412A1 (es) 2004-07-12
AR039570A1 (es) 2005-02-23
NO2015016I2 (no) 2015-07-09
US20030216437A1 (en) 2003-11-20
CA2482858C (en) 2010-11-30
EP1495018A1 (en) 2005-01-12
ES2338171T3 (es) 2010-05-04
DE60317493D1 (en) 2011-01-13
EP2065384A1 (en) 2009-06-03
EP1982984B1 (en) 2013-02-13
EP2065384B1 (en) 2011-01-05
RU2329264C9 (ru) 2009-04-20
EP1982984A2 (en) 2008-10-22
EP1495018B3 (en) 2011-03-16
MY144040A (en) 2011-07-29
CN1659162B (zh) 2011-08-31
EP2062890B1 (en) 2011-01-05
NL300746I2 (enExample) 2016-01-21
WO2003089428A1 (en) 2003-10-30
KR20040099441A (ko) 2004-11-26
SI1495018T1 (sl) 2008-04-30
HK1070887A1 (en) 2005-06-30
AU2003221932A1 (en) 2003-11-03
NZ575139A (en) 2010-08-27
TW200404068A (en) 2004-03-16
BR0309309A (pt) 2005-02-15

Similar Documents

Publication Publication Date Title
KR101026929B1 (ko) 트리사이클릭 트롬빈 수용체 길항제
JP4694490B2 (ja) トロンビンレセプターアンタゴニスト
KR100960170B1 (ko) 트롬빈 수용체 길항제로서의 힘바신 동족체
KR20090074219A (ko) 트롬빈 수용체 길항제로서의 비사이클릭 및 트리사이클릭 유도체
EP1036072B1 (en) Thrombin receptor antagonists
KR20070101216A (ko) 트롬빈 수용체 길항제
AU2008200842B2 (en) Tricyclic thrombin receptor antagonists
HK1070887B (en) Tricyclic thrombin receptor antagonists
HK1131133A (en) Tricyclic thrombin receptor antagonist

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20140227

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20150227

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20151230

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20161229

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20171228

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20181227

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220329

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220329